Format

Send to:

Choose Destination
See comment in PubMed Commons below
Arch Med Res. 2013 May;44(4):266-72. doi: 10.1016/j.arcmed.2013.03.007. Epub 2013 May 15.

Evaluation of cytokines in multiple sclerosis patients treated with mesenchymal stem cells.

Author information

  • 1Research Center of Molecular Immunology, Tehran University of Medical Sciences, Tehran, Iran. mohyeddin@sina.tums.ac.ir

Abstract

BACKGROUND AND AIMS:

Mesenchymal stem cells (MSC) are currently strong candidates for stem cell therapy. Cytokines have a profound effect on the resultant immune responses. This study aims to evaluate variations in the cytokine profile of multiple sclerosis patients treated with autologous MSC.

METHODS:

Twenty five patients received one dose of intrathecal MSCs (mean number: 29.5 × 10⁶). To measure the gene expression of FOXP3, IFN-γ, TGF-β, IL-4, IL-10, IL-6, and their serum proteins, samples were collected at five intervals: day 0 prior to injection and months 1, 3, 6, and 12 after MSC therapy. Gene expression was evaluated via real-time PCR and protein values were measured by ELISA.

RESULTS:

There were no statistically significant variations in gene expression and serum level of cytokines after a 1-year follow-up of MSC-treated MS patients. The only correlation found was an increase in IL-6 gene expression in patients with progressive disease.

CONCLUSION:

Intrathecal injection of MSCs does not affect cytokine variation in peripheral blood. Because the condition of most of our patients either improved or stabilized after stem cell therapy (SCT), we speculate that the immunomodulatory or neuroregenerative effects of MSC are exerted locally in the central nervous system.

Copyright © 2013 IMSS. Published by Elsevier Inc. All rights reserved.

PMID:
23684533
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk